Elucidation of the mechanism of action of chemokines and immune mechanisms in the acquisition of cabazitaxel resistance

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K16728
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Kanazawa University
• Principal Investigator: Iwamoto Hiroaki 金沢大学, 附属病院, 助教 (90847245)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: Cabazitaxel / CRPC / Resistant / CCL2 / Coffee

Outline of Final Research Achievements

Elucidating the mechanism by which CRPC confers resistance to cabazitaxel (CBZ) and developing novel therapeutic strategies is essential for improving the prognosis of prostate cancer patients. RNA microarray results suggest that TP53TG1, a long non-coding RNA, may be involved in the mechanism of CBZ resistance. We also found that coffee-containing anti-inflammatory substances, carweol and cafestol, have inhibitory effects on the proliferation and migration of CBZ-resistant prostate cancer cell lines. The results suggest that the elucidation of this mechanism of action may lead to the elucidation of the mechanism that leads to CBZ resistance.

Free Research Field

前立腺癌

Academic Significance and Societal Importance of the Research Achievements

ドセタキセル治療後のCRPCに対してカバジタキセルは生存期間を有意に延長したが、治療後増悪までの期間は高々2.8箇月と報告されている。進行性前立腺がんに対するカバジタキセルの効果は限定的であり、カバジタキセル抵抗性のメカニズムの解明が急務である。本研究の成果をさらに発展させることで、カバジタキセル耐性のメカニズムの解明につながり、進行性前立腺がんの予後改善に寄与することが期待される。